ReviewChinese journal of cancer research = Chung-kuo yen cheng yen chiu2015
The status, limitation and improvement of adoptive cellular immunotherapy in advanced urologic malignancies.
Review in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 15 citations in OpenAlex.
- Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy.Frontiers in immunology · 2022Review
- CD137Cancers · 2021Review
- Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.Frontiers in immunology · 2020Review
- Magnetic targeting of adoptively transferred tumour-specific nanoparticle-loaded CD8Journal of nanobiotechnology · 2019Article
- Immunogenic Effect of Hyperthermia on Enhancing Radiotherapeutic Efficacy.International journal of molecular sciences · 2018Review
- PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma.Oncoimmunology · 2016Article
- Tracking and Quantification of Magnetically Labeled Stem Cells using Magnetic Resonance Imaging.Advanced functional materials · 2016Article
- Cancer immunotherapy: the beginning of the end of cancer?BMC medicine · 2016Review
- Safety and activity of PD-1 blockade-activated DC-CIK cells in patients with advanced solid tumors.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, immunotherapy has been gradually established as the fourth frequently adopted antitumor therapy, following surgery, chemotherapy and radiotherapy, for advanced urologic malignancies with an improved understanding of theoretical basis, such as molecular biology and immunology. Thereinto, adoptive cellular immunotherapy (ACI) has become one of the hotspots, which comprises a variety of treatment approaches, such as TIL, CIK cell, γδ T cell, CAR-engineered T cell and Allogeneic stem cell transplantation (alloSCT). Although preclinical efficacy has been demonstrated remarkably, clinical trials could not consistently show the benefit due to multi-factors in complex immunosuppressive microenvironment in vivo compared to that of in vitro. Here we review some timely aspects of ACI for advanced urologic malignancies, and describe the current status and limitation of immunotherapy from the cellular level. It's our expectation to provide prompting consideration of novel combinatorial ACI strategies and a resurgence of interest in ACI for advanced urologic malignancies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.